Methods and reagents for the enhancement of virus transduction in the bladder epithelium
Agents and methods for enhancing recombinant virus transduction in the bladder epithelium are described. A first method involves contacting the luminal surface of the bladder with a composition comprising a transduction enhancing agent and an oncolytic virus. Alternatively, the luminal surface of the bladder can be contacted first with a pretreatment composition comprising a transduction enhancing agent and, subsequently, with a composition comprising an oncolytic virus. Bladder treatment compositions comprising a transduction enhancing agent and an oncolytic virus are also described.
1 - 35 . (canceled)
36 . A method of treating cancer of the bladder comprising: contacting the luminal surface of the bladder with a pretreatment composition comprising a transduction enhancing agent having a structure represented by the chemical formula:
wherein x and y are positive integers; and further contacting the luminal surface of the bladder with a composition comprising a replication competent oncolytic virus.
37 . The method of claim 36 , wherein x is 6 and y is an integer between 8 and 10.
38 . The method of claim 37 , wherein the pretreatment composition comprises about 0.02 to about 0.5 wt. % of the transduction enhancing agent.
39 . The method of claim 36 , wherein the oncolytic virus is an oncolytic adenovirus.
40 . The method of claim 39 , wherein the oncolytic adenovirus is CG8840.
41 . The method of claim 3 , wherein the oncolytic virus composition further comprises a chemotherapeutic agent.
42 . The method of claim 41 , wherein the chemotherapeutic agent is docetaxel.
43 . The method of claim 36 , wherein the pretreatment composition further comprises an oxidizing agent.
44 . The method of claim 43 , wherein the oxidizing agent is selected from the group consisting of hypochlorous acid, hydrogen peroxide, and peroxyacetic acid.
45 - 71 . (canceled)
72 . The method of claim 36 , wherein the composition comprising the transduction enhancing agent and the composition comprising the oncolytic virus are co-administered.
73 . The method of claim 36 , wherein the composition comprising the transduction enhancing agent is administered prior to the composition comprising the oncolytic virus.
74 . The method of claim 36 , wherein the transduction enhancing agent is polydocanol.